In conclusion, this study highlights that tocilizumab can be an option to reduce GC exposure in GCA patients over 80 years old. Mild-to-moderate adverse events are observed in one-third of patients and thus require constant vigilance.
The following authors included registered patients who were not selected in this study: Christian Agard (Nantes), Jean-François Alexandra (Paris), Laurent Alric (Toulouse), Daniel Blockmans (Leuven, Belgique), Bernard Bonnotte (Dijon), Laurence Bouillet (Grenoble), Cyril Confavreux (Lyon), Philippe Guilpain (Montpellier), Thomas Hanslik (Paris), François-Xavier Lapébie (Toulouse), Martin Michaud (Toulouse), Claire de Moreuil (Brest), Thomas Moulinet (Nancy), David Saadoun (Paris), Damien Sene (Paris), and Mathieu Vautier (Paris).
No specific funding was received from any funding bodies in the public, commercial, or not-for-profit sectors to carry out the work described in this manuscript.
Availability of data and materials
Data are available to request.
Ethics approval and consent to participate
The Caen Ethical Board approved the study (CLERS ID265).
Consent for publication
Each patient included in this study received written information and no patient objected to this study.
Arthritis Res Ther. 2021;23(143) © 2021 BioMed Central, Ltd.
Copyright to this article is held by the author(s), licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original citation.